Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects
- PMID: 10195789
- DOI: 10.1016/s0264-410x(98)00362-4
Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects
Abstract
Measles antibody seroprevalence was compared in Innu, Inuit, and Caucasian peoples of northern Newfoundland, Canada, who were immunized with a single dose of M-M-R-II (Merck Research Laboratories) vaccine. Healthy, volunteer schoolchildren (n = 606) were enrolled. Measles antibody was measured with a whole virus measles-specific IgG EIA. Native (Innu and Inuit) schoolchildren (n = 253) had a significantly higher seropositive rate (83%) after a single dose of measles vaccine compared to Caucasian (n = 353) children (76%; p = 0.025), and higher mean antibody levels after immunization compared to Caucasian children (1.74 EIA units, vs. 1.63; p = 0.06). Caucasian children were more likely to have been immunized after age 15 months (20.6% vs. 9.6%; p = 0.001). There was no significant difference in the mean time interval between immunization and blood sampling for natives versus Caucasian (8.0 years vs. 7.95 years; p = 0.49). After adjustment for time from immunization and age at immunization, there remained a marginally significant racial difference in seropositivity (OR = 1.65, 95% CI 0.96, 2.83, p = 0.068). The unadjusted odds ratio for seropositivity (comparing natives vs. non-natives, combining negative and equivocal results) was 1.66 (95% CI 1.06-2.59, p = 0.018). The higher measles-seropositive rate found among native compared to non-native Canadian children suggests that genetic and/or environmental factor(s) affect circulating antibody levels following immunization. The determination of these sources of variability may lead to the development of more efficacious vaccines or delivery strategies.
Similar articles
-
Measles reimmunization in children seronegative after initial immunization.JAMA. 1997 Apr 9;277(14):1156-8. JAMA. 1997. PMID: 9087472 Clinical Trial.
-
Effect of differing immunization policies on circulating measles antibody levels in US and Canadian children.Mayo Clin Proc. 2002 May;77(5):446-52. doi: 10.4065/77.5.446. Mayo Clin Proc. 2002. PMID: 12004994
-
Predicting and comparing long-term measles antibody profiles of different immunization policies.Bull World Health Organ. 2001;79(7):615-24. Bull World Health Organ. 2001. PMID: 11477964 Free PMC article.
-
Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.Pediatr Infect Dis J. 1996 Aug;15(8):687-92. doi: 10.1097/00006454-199608000-00010. Pediatr Infect Dis J. 1996. PMID: 8858673
-
The resurgence of measles in the United States, 1989-1990.Annu Rev Med. 1992;43:451-63. doi: 10.1146/annurev.me.43.020192.002315. Annu Rev Med. 1992. PMID: 1580601 Review.
Cited by
-
Robust immune response to COVID-19 vaccination in the island population of Greenland.Commun Med (Lond). 2024 Sep 6;4(1):173. doi: 10.1038/s43856-024-00602-y. Commun Med (Lond). 2024. PMID: 39242878 Free PMC article.
-
Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis.EClinicalMedicine. 2023 Apr;58:101926. doi: 10.1016/j.eclinm.2023.101926. Epub 2023 Apr 4. EClinicalMedicine. 2023. PMID: 37034357 Free PMC article.
-
Advances in Oral Subunit Vaccine Design.Vaccines (Basel). 2020 Dec 22;9(1):1. doi: 10.3390/vaccines9010001. Vaccines (Basel). 2020. PMID: 33375151 Free PMC article. Review.
-
Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study.Hum Vaccin Immunother. 2019;15(2):317-326. doi: 10.1080/21645515.2018.1536588. Epub 2018 Nov 15. Hum Vaccin Immunother. 2019. PMID: 30431387 Free PMC article. Clinical Trial.
-
Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination.Vaccine. 2016 Sep 22;34(41):4913-4919. doi: 10.1016/j.vaccine.2016.08.060. Epub 2016 Aug 30. Vaccine. 2016. PMID: 27591105 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources